{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T00:24:07Z","timestamp":1795047847465,"version":"4.10.2"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"14","license":[{"start":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T00:00:00Z","timestamp":1508716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,7]]},"DOI":"10.1093\/eurheartj\/ehx566","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T15:12:07Z","timestamp":1505747527000},"page":"1172-1180","source":"Crossref","is-referenced-by-count":198,"title":["Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials"],"prefix":"10.1093","volume":"39","author":[{"given":"Konstantinos C","family":"Koskinas","sequence":"first","affiliation":[{"name":"Department of Cardiology, University Hospital Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George C M","family":"Siontis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Piccolo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Mavridis","sequence":"additional","affiliation":[{"name":"Department of Primary Education, University of Ioannina, Ioannina, Greece"},{"name":"Centre de Recherche \u00c9pid\u00e9miologie et Statistique Sorbonne Paris Cit\u00e9 (CRESS-UMR1153), Inserm\/Universit\u00e9 Paris Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"R\u00e4ber","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mach","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Geneva University Hospital, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Bern, 3010 Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,10,23]]},"reference":[{"key":"key\n\t\t\t\t20180407055351_ehx566-B1","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B2","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B3","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B4","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","article-title":"2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B6","first-page":"2245","article-title":"European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk","volume":"38","author":"Landmesser","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B7","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B8","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis","volume":"37","author":"Lipinski","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t20180407055351_ehx566-B10","author":"Higgins"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B11","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B12","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"Pt A","key":"key\n\t\t\t\t20180407055351_ehx566-B13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B14","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B15","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1136\/bmj.318.7197.1548","article-title":"Numbers needed to treat derived from meta-analyses\u2014sometimes informative, usually misleading","volume":"318","author":"Smeeth","year":"1999","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B18","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.jcin.2017.06.001","article-title":"Risk of early adverse events after clopidogrel discontinuation in patients undergoing short-term dual antiplatelet therapy. an individual participant data analysis","volume":"10","author":"Piccolo","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/eb-2013-101700","article-title":"Exploring and accounting for publication bias in mental health: a brief overview of methods","volume":"17","author":"Mavridis","year":"2014","journal-title":"Evid Based Ment Health"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B20","first-page":"1383","article-title":"4S randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B21","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199701163360301","article-title":"The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts","volume":"336","author":"The Post Coronary Artery Bypass Graft Trial Investigators","year":"1997","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B23","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"The Long-Term Intervention with Pravastatin in Ischaemic Disease Study Group","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B24","first-page":"810","article-title":"Results of the low-dose (20\u2009mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Infarto Miocardico)","volume":"1","author":"GISSI Prevenzione Investigators","year":"2000","journal-title":"Ital Heart J"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B25","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1001\/jama.287.24.3215","article-title":"Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial","volume":"287","author":"Serruys","year":"2002","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20\u2009536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B27","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1185\/030079902125000787","article-title":"Treatment with atorvastatin to the National Cholesterol Educational Program goal versus \u2018usual\u2019 care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study","volume":"18","author":"Athyros","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B28","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B29","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z Trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B30","first-page":"1772","article-title":"Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study","volume":"44","author":"Koren","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B31","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B32","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B33","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B34","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80\u2009mg versus 20\u2009mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","author":"Armitage","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B35","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes.","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B36","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t20180407055351_ehx566-B37","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B38","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B39","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamainternmed.2015.7248","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors for treatment of high cholesterol levels: effectiveness and value","volume":"176","author":"Tice","year":"2016","journal-title":"JAMA Intern Med"},{"key":"key\n\t\t\t\t20180407055351_ehx566-B41","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/eurheartj\/ehw150","article-title":"LDL-cholesterol targets: perspectives for the use of PCSK9 inhibitors","volume":"37","author":"L\u00fcscher","year":"2016","journal-title":"Eur Heart J."}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/39\/14\/1172\/24554051\/ehx566.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,7]],"date-time":"2018-04-07T05:54:04Z","timestamp":1523080444000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/39\/14\/1172\/4562493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,23]]},"references-count":41,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2017,10,23]]},"published-print":{"date-parts":[[2018,4,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehx566","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4,7]]},"published":{"date-parts":[[2017,10,23]]}}}